[en] Conventional endocervical adenocarcinoma in situ (cAIS) is typically strongly and diffusely positive for p16 with a high Ki67 index consistent with its frequent association with high-risk human papillomavirus (HPV) infection. The intestinal variant (iAIS) is less common, and its relationship to HPV infection has not been thoroughly examined. This study compares the clinicopathologic features, frequency of HPV infection, and expression of CDX2 and surrogate biomarkers of HPV infection (p16, Ki67) in cAIS with those of iAIS. A total of 86 cases with a diagnosis of AIS (49 iAIS, 37 cAIS) were identified from our multi-institutional files. Of these, 13 iAIS and 20 cAIS cases had slides and tissue available for histopathologic review, immunohistochemical analysis, and molecular tests. All 86 cases were used to evaluate clinical parameters; however, HPV DNA analysis and immunohistochemical analysis for p16, MIB-1, CDX2, and p53 were performed only on those cases with available slides or paraffin blocks. The average age at diagnosis was significantly higher in iAIS compared with that in cAIS (44.5 vs. 32.6 y) (P=0.0001). All 20 cAIS cases showed moderate to strong and diffuse p16 staining; however, only 9/13 iAIS cases showed this degree of p16 staining, whereas 4/13 (31%) iAIS cases showed weak and patchy distribution (P<0.02). Only 6/9 (67%) iAIS cases were positive for either HPV type 18 (5) or 33 (1), in contrast to 11/11 conventional cAIS (P=0.04). Similarly, 12/14 cAIS, but only 5/13 iAIS, cases showed a high Ki67 proliferative index. CDX2 was positive in all iAIS cases, whereas p53 was negative. Most iAIS cases are positive for high-risk HPV and show moderate to strong and diffuse p16 staining; however, a subset of iAIS shows variable staining with p16 and Ki67, is not associated with HPV, and occurs in a distinctly older age group suggesting an alternative pathogenesis. Awareness that iAIS can show variable staining for p16 and Ki67 is important when resolving problematic endocervical lesions, particularly in small biopsies with unusual p16 staining patterns.
Disciplines :
Oncology
Author, co-author :
Howitt, Brooke E.
Herfs, Michael ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Brister, Kathriel
Oliva, Esther
Longtine, Janina
Hecht, Jonathan L.
Nucci, Marisa R.
Language :
English
Title :
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women.
Publication date :
2013
Journal title :
American Journal of Surgical Pathology
ISSN :
0147-5185
eISSN :
1532-0979
Publisher :
Lippincott Williams & Wilkins, United States - New York
Andersen ES, Arffmann E. Adenocarcinoma in situ of the uterine cervix: a clinico-pathologic study of 36 cases. Gynecol Oncol. 1989;35:1-7.
Bertrand M, Lickrish GM, Colgan TJ. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol. 1987;157:21-25.
Jaworski RC, Pacey NF, Greenberg ML, et al. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri. Adenocarcinoma in situ. Cancer. 1988;61:1171-1181.
Ostor AG, Pagano R, Davoren RA, et al. Adenocarcinoma in situ of the cervix. Int J Gynecol Pathol. 1984;3:179-190.
Ostor AG, Duncan A, Quinn M, et al. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol. 2000;79:207-210.
Tobon H, Dave H. Adenocarcinoma in situ of the cervix. Clinicopa-thologic observations of 11 cases. Int J Gynecol Pathol. 1988;7:139-151.
Lee KR, Flynn CE. Early invasive adenocarcinoma of the cervix. Cancer. 2000;89:1048-1055.
Park KJ, Kiyokawa T, Soslow RA, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35:633-646.
Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
Quint KD, de Koning MN, Geraets DT, et al. Comprehensive analysis of human papillomavirus and chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol. 2009;114:390-394.
Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol. 2002;33:899-904.
McCluggage WG, Shah R, Connolly LE, et al. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol. 2008;27:92-100.
Schlesinger C, Silverberg SG. Endocervical adenocarcinoma in situ of tubal type and its relation to atypical tubal metaplasia. Int J Gynecol Pathol. 1999;18:1-4.
Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185-207.
Zaino RJ. Glandular lesions of the uterine cervix. Mod Pathol. 2000;13:261-274.
Houghton O, Jamison J, Wilson R, et al. p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology. 2010;57:342-350.
Tavassoli FA, Devilee P, et al. World Health Organization: Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
Witkiewicz A, Lee KR, Brodsky G, et al. Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS. Am J Surg Pathol. 2005;29:1609-1614.
Du J, Nasman A, Carlson JW, et al. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003-2008 in Stockholm, Sweden, before public HPV vaccination. Acta Oncol. 2011;50: 1215-1219.
Kusanagi Y, Kojima A, Mikami Y, et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarci-noma with gastric morphology and phenotype. Am J Pathol. 2010;177:2169-2175.
Kawauchi S, Kusuda T, Liu XP, et al. Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immuno-histochemical study. Am J Surg Pathol. 2008;32:1807-1815.
Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003;27: 187-193.
Pavlakis K, Messini I, Athanassiadou S, et al. Endocervical glandular lesions: a diagnostic approach combining a semi-quantitative scoring method to the expression of CEA, MIB-1 and p16. Gynecol Oncol. 2006;103:971-976.
Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201:535-543.
Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. 2006;94:171-175.
Hadzisejdc I, Krasevic M, Haller H, et al. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Antropol. 2007;31(suppl 2):97-102.
Sullivan LM, Smolkin ME, Frierson HF Jr, et al. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immuno-positivity in the absence of overt colorectal morphology. Am J Surg Pathol. 2008;32:1608-1612.
Mikami Y, Kiyokawa T, Hata S, et al. Gastrointestinal immuno-phenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and 'adenoma malignum'. Mod Pathol. 2004;17:962-972.
Saad RS, Ismiil N, Dube V, et al. CDX2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol. 2009;132:531-538.
Kojima A, Mikami Y, Sudo T, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarci-noma of the uterine cervix. Am J Surg Pathol. 2007;31:664-672.